Endocrine Abstracts

Background: Opioid analgesics are commonly used for chronic non-cancer pain but may impair gonadal and adrenal axis function. We measured pituitary function, rates of hormone deficiency, sexual function and quality of life (QoL) in patients on oral or transdermal opioids versus age and sex-matched controls.Methods: Participants with chronic non-malignant pain receiving oral or transdermal opioids for more than six m...

Background: Opioid analgesics are commonly used for chronic non-cancer pain but may impair gonadal and adrenal axis function. We measured pituitary function, rates of hormone deficiency, sexual function and quality of life (QoL) in patients on oral or transdermal opioids versus age and sex-matched controls.Methods: Participants with chronic non-malignant pain receiving oral or transdermal opioids for more than six m...

ARMC5 mutations are associated with PBMAH risks, but the ARMC5 action mechanism remains unknown. We discovered that ARMC5 was part of a novel ubiquitin ligase (E3) specific for RPB1, the largest Pol II subunit. ARMC5 deletion significantly reduced RPB1 ubiquitination and increased RPB1 accumulation. Surprisingly, the degradation of not only RPB1 but all the 12 subunits of Pol II was compromised in the absence of ARMC5, suggesting that this E3 acts on RPB1 and molecules in its ...

ATL1103 is a second generation antisense 20mer intended to inhibit expression of the GH receptor (GHR) gene. Phosphorothioate and 2′-O-methoxyethyl modifications to nucleotides increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We previously reported a phase 2, randomised, open-label, parallel group study of ATL1103 in 26 patients with acromegaly which demonstrated a fall in serum IGF-I of 26% with 200 mg twice w...

ATL1103 is a second generation antisense oligomer directed at the GH receptor. It is a 20mer with a phosphorothioate backbone and 2′-O-methoxyethyl modifications of the five nucleotides at either end intended to increase its plasma half-life and affinity for the target RNA to allow post-hybridization RNaseH degradation. We report a phase 2 randomised, open-label, parallel group study of subcutaneously administered ATL1103 in patients with active acromegaly. Appr...